Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rocky Mountain Biosystems has received a grant award of approximately $600,000 over two years from the National Institute of Allergy and Infectious Diseases at the National Institutes of Health or NIH to develop its Self-Administered Vaccination Electromechanical or SAVE technology for influenza vaccination.
Subscribe to our email newsletter
In the event of a pandemic, this needle-free system could be rapidly disseminated to provide protection against a deadly influenza outbreak, such as H5N1 influenza or bird flu. Company’s technology has the potential to improve vaccine effectiveness to protect against a range of agents, including potential bioterror agents, by delivering therapeutics directly through the skin without needles, thus reducing required dosage and extending vaccine supplies.
Kevin Marchitto, CEO of Rocky Mountain, said: “With SAVE technology, we believe we can deliver vaccine protection to nearly all of the US population within days of an outbreak. In addition, the effectiveness of technology may reduce the amount of vaccine required, as well as provide greater immunity to the very young and elderly.”